Header Logo

Connection

Jan Smogorzewski to Infliximab

Back to Details
This is a "connection" page, showing publications Jan Smogorzewski has written about Infliximab.
Jan Smogorzewski
Connection Strength
0.172
Infliximab
  1. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases. Dermatol Ther. 2021 05; 34(3):e14883.
    View in: PubMed
    Score: 0.172
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.